Ken Griffin Ascendis Pharma A/S Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Citadel Advisors LLC holds 19,800 shares of ASND stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,800

Previous 32,600 39.26%

Holding current value

$2.7 Million

Previous $4.45 Million 33.5%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $14.3 Million - $19.4 Million	126,162 Added 23.46%	663,924 $99.2 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $9.72 Million - $12.3 Million	80,258 Added 17.54%	537,762 $73.3 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $35.3 Million - $45.6 Million	285,933 Added 166.66%	457,504 $69.2 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $14.8 Million - $21.8 Million	171,323 Added 69081.85%	171,571 $21.6 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $1.19 Million - $1.43 Million	-13,724 Reduced 98.23%	248 $23,000
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $7.49 Million - $10.5 Million	-107,030 Reduced 88.45%	13,972 $1.25 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $14.2 Million - $17.2 Million	-135,284 Reduced 52.79%	121,002 $13 Million
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $20.1 Million - $26.7 Million	202,346 Added 375.13%	256,286 $31.3 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $272,929 - $358,027	-3,248 Reduced 5.68%	53,940 $5.57 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $403,048 - $607,102	5,162 Added 9.92%	57,188 $5.32 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $5.45 Million - $7.27 Million	42,848 Added 466.86%	52,026 $7 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $31.6 Million - $49.6 Million	-280,497 Reduced 96.83%	9,178 $1.46 Million
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $21.3 Million - $25.4 Million	174,760 Added 152.08%	289,675 $38.1 Million
Q1 2021 May 17, 2021	SELL	$124.92 - $173.33 $25.6 Million - $35.5 Million	-205,099 Reduced 64.09%	114,915 $14.8 Million
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $27 Million - $32.6 Million	-178,373 Reduced 35.79%	320,014 $53.4 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $3.24 Million - $3.73 Million	24,144 Added 5.09%	498,387 $76.9 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $25.2 Million - $35.5 Million	227,543 Added 92.23%	474,243 $70.1 Million
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $8.05 Million - $12 Million	-82,982 Reduced 25.17%	246,700 $27.8 Million
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $29.4 Million - $44.7 Million	320,970 Added 3684.23%	329,682 $45.9 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $6.07 Million - $7.53 Million	-63,356 Reduced 87.91%	8,712 $839,000
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $25 Million - $30.9 Million	-233,808 Reduced 76.44%	72,068 $8.3 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $13 Million - $27.2 Million	209,267 Added 216.61%	305,876 $0
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $4.79 Million - $6.04 Million	86,760 Added 880.9%	96,609 $6.05 Million
Q3 2018 Nov 13, 2018	SELL	$63.77 - $76.28 $1.07 Million - $1.28 Million	-16,829 Reduced 63.08%	9,849 $0
Q2 2018 Aug 10, 2018	BUY	$58.55 - $73.92 $1.56 Million - $1.97 Million	26,678 New	26,678 $0
Q4 2017 Feb 09, 2018	SELL	$31.98 - $40.38 $328,530 - $414,823	-10,273 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$26.89 - $37.1 $276,240 - $381,128	10,273	10,273 $372,000

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account